Darbepoetin alfa for anemia in chronic kidney disease
- PMID: 24422692
- DOI: 10.1586/17512433.1.3.369
Darbepoetin alfa for anemia in chronic kidney disease
Abstract
Anemia of chronic kidney disease (CKD) is common, yet it is often under-recognized and undertreated, with serious adverse consequences. It is highly responsive to treatment with erythropoiesis-stimulating agents (ESAs). Darbepoetin alfa is a hyperglycosylated ESA that has a lower affinity to the erythropoietin receptor but a longer half-life than recombinant human erythropoietin, irrespective of administration by a subcutaneous or intravenous route. Owing to its pharmacokinetic characteristics, darbepoetin alfa has been used in extended dosing intervals ranging from once every week to once every 4 weeks in CKD patients on dialysis, as well as in CKD patients not on dialysis. Darbepoetin alfa has been shown to be safe and effective in clinical trials. The safety profile of darbepoetin alfa is similar to that of recombinant human erythropoietin. While _target hemoglobin levels in CKD anemia remain debatable, treatment of anemia with ESAs has the proven benefits of reducing transfusions and improving quality of life. Darbepoetin alfa has the potential to simplify the treatment of CKD anemia with many advantages, including infrequent dosing, improved patient convenience and compliance, and decreased healthcare resource utilization.
Similar articles
-
Darbepoetin alfa: a novel erythropoiesis-stimulating protein.Drugs Today (Barc). 2003 Jul;39(7):477-95. doi: 10.1358/dot.2003.39.7.799441. Drugs Today (Barc). 2003. PMID: 12973399 Review.
-
Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).Am J Nephrol. 2006;26(2):149-56. doi: 10.1159/000092852. Epub 2006 Apr 21. Am J Nephrol. 2006. PMID: 16636531 Clinical Trial.
-
Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.Nephrol Dial Transplant. 2004 May;19(5):1224-30. doi: 10.1093/ndt/gfh106. Epub 2004 Feb 19. Nephrol Dial Transplant. 2004. PMID: 14993489 Clinical Trial.
-
[Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].Nephrol Ther. 2006 Sep;2(4):191-9. doi: 10.1016/j.nephro.2006.06.004. Epub 2006 Aug 17. Nephrol Ther. 2006. PMID: 16966064 Clinical Trial. French.
-
Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.Mayo Clin Proc. 2007 Nov;82(11):1371-80. doi: 10.4065/82.11.1371. Mayo Clin Proc. 2007. PMID: 17976358 Review.
Cited by
-
Soluble Fas affects erythropoiesis in vitro and acts as a potential predictor of erythropoiesis-stimulating agent therapy in patients with chronic kidney disease.Am J Physiol Renal Physiol. 2020 Apr 1;318(4):F861-F869. doi: 10.1152/ajprenal.00433.2019. Epub 2020 Jan 31. Am J Physiol Renal Physiol. 2020. PMID: 32003597 Free PMC article.
LinkOut - more resources
Full Text Sources
